- 1. Name of the medicinal product
- 2. Qualitative and quantitative composition
- 3. Pharmaceutical form
- 4. Clinical particulars
- 4.1 Therapeutic indications
- 4.2 Posology and method of administration
- 4.3 Contraindications
- 4.4 Special warnings and precautions for use
- 4.5 Interaction with other medicinal products and other forms of interaction
- 4.6 Fertility, pregnancy and lactation
- 4.7 Effects on ability to drive and use machines
- 4.8 Undesirable effects
- 4.9 Overdose
- 5. Pharmacological properties
- 5.1 Pharmacodynamic properties
- 5.2 Pharmacokinetic properties
- 5.3 Preclinical safety data
- 6. Pharmaceutical particulars
- 6.1 List of excipients
- 6.2 Incompatibilities
- 6.3 Shelf life
- 6.4 Special precautions for storage
- 6.5 Nature and contents of container
- 6.6 Special precautions for disposal and other handling
- 7. Marketing authorisation holder
- 8. Marketing authorisation number(s)
- 9. Date of first authorisation/renewal of the authorisation
- 10. Date of revision of the text
1. Name of the medicinal product
MOVICOL Plain 13.7g sachet, powder for oral solution
2. Qualitative and quantitative composition
Each sachet of MOVICOL Plain contains the following active substances:
The content of electrolyte ions per sachet when made up to 125 ml of solution is as follows:
|Macrogol 3350||13.1250 g|
|Sodium Chloride||0.3508 g|
|Sodium Hydrogen Carbonate||0.1786 g|
|Potassium Chloride||0.0502 g|
|Hydrogen Carbonate||17 mmol/l|
3. Pharmaceutical form
Powder for oral solution. Free flowing white powder.
4. Clinical particulars
4.1 Therapeutic indications
For the treatment of chronic constipation. MOVICOL Plain is also effective in resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon.
4.2 Posology and method of administration
Chronic ConstipationA course of treatment for constipation with MOVICOL Plain does not normally exceed two weeks, although this can be repeated if required.As for all laxatives, prolonged use is not usually recommended. Extended use may be necessary in the care of patients with severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson's Disease, or induced by regular constipating medication, in particular opioids and antimuscarinics.Adults, adolescents and older people: 1-3 sachets daily in divided doses, according to individual response. For extended use, the dose can be adjusted down to 1 or 2 sachets daily.Children (below 12 years old): Not recommended. Alternative MOVICOL products are available for children.
Faecal impactionA course of treatment for faecal impaction with MOVICOL Plain does not normally exceed 3 days.Adults, adolescents and older people: 8 sachets daily, all of which should be consumed within a 6 hour period.Children (below 12 years old): Not recommended. Alternative MOVICOL products are available for children.Patients with impaired cardiovascular function: For the treatment of faecal impaction the dose should be divided so that no more than two sachets are taken in any one hour.Patients with renal insufficiency: No dosage change is necessary for treatment of either constipation or faecal impaction.
Method of administrationEach sachet should be dissolved in 125ml water. For use in faecal impaction 8 sachets may be dissolved in 1 litre water.
Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease and ulcerative colitis and toxic megacolon.Hypersensitivity to the active substances.
4.4 Special warnings and precautions for use
The fluid content of MOVICOL Plain when re-constituted with water does not replace regular fluid intake and adequate fluid intake must be maintained.Diagnosis of impaction/faecal loading of the rectum should be confirmed by physical or radiological examination of the abdomen and rectum.Mild adverse drug reactions are possible as indicated in Section 4.8. If patients develop any symptoms indicating shifts of fluid/electrolytes (e.g. oedema, shortness of breath, increasing fatigue, dehydration, cardiac failure) MOVICOL Plain should be stopped immediately and electrolytes measured, and any abnormality should be treated appropriately. The absorption of other medicinal products could transiently be reduced due to an increase in gastro-intestinal transit rate induced by MOVICOL Plain (see section 4.5).
4.5 Interaction with other medicinal products and other forms of interaction
Macrogol raises the solubility of medicinal products that are soluble in alcohol and relatively insoluble in water. There is a possibility that the absorption of other medicinal products could be transiently reduced during use with MOVICOL Plain (see section 4.4).There have been isolated reports of decreased efficacy with some concomitantly administered medicinal products, e.g. anti-epileptics.
4.6 Fertility, pregnancy and lactation
PregnancyThere are limited amount of data from the use of MOVICOL in pregnant women. Studies in animals have shown indirect reproductive toxicity (see section 5.3). Clinically, no effects during pregnancy are anticipated, since systemic exposure to macrogol 3350 is negligible.MOVICOL can be used during pregnancy.BreastfeedingNo effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Macrogol 3350 is negligible.MOVICOL can be used during breast-feeding. FertilityThere are no data on the effects of MOVICOL on fertility in humans. There were no effects on fertility in studies in male and female rats (see section 5.3).
4.7 Effects on ability to drive and use machines
MOVICOL Plain has no influence on the ability to drive and use machines.
4.8 Undesirable effects
Reactions related to the gastrointestinal tract occur most commonly. These reactions may occur as a consequence of expansion of the contents of the gastrointestinal tract, and an increase in motility due to the pharmacologic effects of MOVICOL Plain. Mild diarrhoea usually responds to dose reduction.The frequency of the adverse effects is not known as it cannot be estimated from the available data.
|System Organ Class||Adverse Event|
|Immune system disorders||Allergic reactions, including anaphylactic reaction, dyspnoea and skin reactions (see below).|
|Skin and subcutaneous tissue disorders||Allergic skin reactions including angioedema, urticaria, pruritus, rash,erythema.|
|Metabolism and nutrition disorders||Electrolyte disturbances, particularly hyperkalaemia and hypokalaemia.|
|Nervous system disorders||Headache|
|Gastrointestinal disorders||Abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, abdominal distension, borborygmi, flatulence and anorectal discomfort.|
|General disorders and administration site conditions||Peripheral oedema|
Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard.
Severe abdominal pain or distension can be treated by nasogastric aspiration. Extensive fluid loss by diarrhoea or vomiting may require correction of electrolyte disturbances.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Osmotically acting laxatives.ATC code: A06A D65Macrogol 3350 acts by virtue of its osmotic action in the gut, which induces a laxative effect. Macrogol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the softened stools and a facilitation of the defaecation. Electrolytes combined with macrogol 3350 are exchanged across the intestinal barrier (mucosa) with serum electrolytes and excreted in faecal water without net gain or loss of sodium, potassium and water. For the indication of faecal impaction controlled comparative studies have not been performed with other treatments (e.g. enemas). In a non-comparative study in 27 adult patients, MOVICOL cleared the faecal impaction in 12/27 (44%) after 1 day's treatment; 23/27 (85%) after 2 days' treatment and 24/27 (89%) at the end of 3 days.Clinical studies in the use of MOVICOL in chronic constipation have shown that the dose needed to produce normal formed stools tends to reduce over time. Many patients respond to between 1 and 2 sachets a day, but this dose should be adjusted depending on individual response.
5.2 Pharmacokinetic properties
Macrogol 3350 is unchanged along the gut. It is virtually unabsorbed from the gastro-intestinal tract. Any macrogol 3350 that is absorbed is excreted via the urine.
5.3 Preclinical safety data
Preclinical studies provide evidence that macrogol 3350 has no significant systemic toxicity potential, based on conventional studies of pharmacology, repeated dose toxicity and genotoxicity. There were no direct embryotoxic or teratogenic effects in rats even at maternally toxic levels that are a multiple of 66 x the maximum recommended dose in humans for chronic constipation and 25 x for faecal impaction. Indirect embryofetal effects, including reduction in fetal and placental weights, reduced fetal viability, increased limb and paw hyperflexion and abortions, were noted in the rabbit at a maternally toxic dose that was 3.3 x the maximum recommended dose in humans for treatment of chronic constipation and 1.3 x for faecal impaction. Rabbits are a sensitive animal test species to the effects of GI-acting substances and the studies were conducted under exaggerated conditions with high dose volumes administered, which are not clinically relevant. The findings may have been a consequence of an indirect effect of MOVICOL related to poor maternal condition as the result of an exaggerated pharmacodynamic response in the rabbit. There was no indication of a teratogenic effect.There are long-term animal toxicity and carcinogenicity studies involving macrogol 3350. Results from these and other toxicity studies using high levels of orally administered high molecular weight macrogols provide evidence of safety at the recommended therapeutic dose.
6. Pharmaceutical particulars
6.1 List of excipients
None are known.
6.3 Shelf life
3 years. Reconstituted solution: 24 hours.
6.4 Special precautions for storage
Sachet: Do not store above 25°C.Reconstituted solution: Store at 2-8°C (in a refrigerator and covered).
6.5 Nature and contents of container
Each sachet contains 13.7 g of powder.Sachet: laminate consisting of four layers: low density polyethylene, aluminium, low density polyethylene and paper.Pack sizes: boxes of 6, 8, 10, 20, 30, 40, 50, 60 or 100 sachets.Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
Any unused solution should be discarded within 24 hours.
7. Marketing authorisation holder
Norgine BVHogehilweg 71101 CA Amsterdam ZOThe Netherlands
8. Marketing authorisation number(s)
9. Date of first authorisation/renewal of the authorisation
12 September 2006 / 25 January 2011
10. Date of revision of the text
Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex, UB9 6NS
+44 (0)1895 825 865
Medical Information e-mail
+44 (0)1895 826 600